Fate Therapeutics Inc. (NASDAQ:FATE) has a beta value of 1.62 and has seen 1,242,922 shares traded in the last trading session. The company, currently valued at $8.21 Billion, closed the last trade at $87.39 per share which meant it gained $1.52 on the day or 1.77% during that session. The FATE stock price is -38.64% off its 52-week high price of $121.16 and 72.97% above the 52-week low of $23.62. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.54 Million shares traded. The 3-month trading volume is 1.11 Million shares.
The consensus among analysts is that Fate Therapeutics Inc. (FATE) is an Overweight stock at the moment, with a recommendation rating of 1.9. None of the analysts rate the stock as a Sell, while none rate it as Overweight. 5 out of 17 have rated it as a Hold, with 12 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is -$0.43.
Fate Therapeutics Inc. (NASDAQ:FATE) trade information
Sporting 1.77% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, Apr 26 when the FATE stock price touched $94.96- or saw a rise of 7.97%. Year-to-date, Fate Therapeutics Inc. shares have moved -3.89%, while the 5-day performance has seen it change 2.4%. Over the past 30 days, the shares of Fate Therapeutics Inc. (NASDAQ:FATE) have changed 17.95%. Short interest in the company has seen 12.07 Million shares shorted with days to cover at 10.87.
Wall Street analysts have a consensus price target for the stock at $114.24, which means that the shares’ value could jump 30.72% from current levels. The projected low price target is $88 while the price target rests at a high of $145. In that case, then, we find that the current price level is +65.92% off the targeted high while a plunge would see the stock lose 0.7% from current levels.
Fate Therapeutics Inc. (FATE) estimates and forecasts
Figures show that Fate Therapeutics Inc. shares have outperformed across the wider relevant industry. The company’s shares have gained +94.07% over the past 6 months, with this year growth rate of 12.38%, compared to 8.1% for the industry. Other than that, the company has, however Increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 2.3% and -28.6% for the next quarter. Revenue growth from the last financial year stood is estimated to be -20.9%.
15 analysts offering their estimates for the company have set an average revenue estimate of $5.9 Million for the current quarter. 15 have an estimated revenue figure of $5.93 Million for the next quarter concluding in June 01, 2021. Year-ago sales stood $2.52 Million and $13.23 Million respectively for this quarter and the next, and analysts expect sales will grow by 134.6% for the current quarter and -55.2% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -12.3% over the past 5 years. Earnings growth for 2021 is a modest -46.2% while over the next 5 years, the company’s earnings are expected to increase by -11.3%.
Fate Therapeutics Inc. (NASDAQ:FATE)’s Major holders
Insiders own 1.69% of the company shares, while shares held by institutions stand at 95.59% with a share float percentage of 97.23%. Investors are also buoyed by the number of investors in a company, with Fate Therapeutics Inc. having a total of 362 institutions that hold shares in the company. The top two institutional holders are Redmile Group, LLC with over 12.63 Million shares worth more than $1.15 Billion. As of December 30, 2020, Redmile Group, LLC held 13.45% of shares outstanding.
The other major institutional holder is FMR, LLC, with the holding of over 7.6 Million shares as of December 30, 2020. The firm’s total holdings are worth over $691.51 Million and represent 8.1% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are ARK ETF Tr-ARK Genomic Revolution ETF and ARK ETF Tr-ARK Innovation ETF. As of March 30, 2021, the former fund manager holds about 4% shares in the company for having 3755311 shares of worth $309.63 Million while later fund manager owns 2.87 Million shares of worth $236.84 Million as of March 30, 2021, which makes it owner of about 3.06% of company’s outstanding stock.